10,645 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Amica Mutual Insurance Co.

Amica Mutual Insurance Co. bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 10,645 shares of the biotechnology company’s stock, valued at approximately $183,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC purchased a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $31,000. National Bank of Canada FI acquired a new stake in ADMA Biologics during the 3rd quarter valued at $35,000. GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter worth $35,000. Finally, Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics during the fourth quarter valued at $51,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 2.6 %

ADMA Biologics stock opened at $19.70 on Thursday. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $4.66 billion, a PE ratio of 70.36 and a beta of 0.60. The firm’s 50 day moving average price is $16.97 and its two-hundred day moving average price is $18.11.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.